FDA Panel Fails to Support Novel Opioid for Depression

An FDA advisory panel failed to endorse the approval of a novel opioid to treat major depressive disorder because of insufficient efficacy data.
News Alerts

Source link

Related posts

Efficacy of Raltegravir in Preventing Progression of Relapsing Remitting MS


UF Health named Parkinson’s Research Center of Excellence


A dozen years of evolution of neurology clerkships in the United States: Looking up


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World